Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/37436
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPOPESCU, Veronica-
dc.contributor.authorBeirinckx, Annemie-
dc.contributor.authorDecallonne, Brigitte-
dc.date.accessioned2022-06-02T14:03:56Z-
dc.date.available2022-06-02T14:03:56Z-
dc.date.issued2022-
dc.date.submitted2022-05-20T09:59:18Z-
dc.identifier.citationActa neurologica belgica, 122 (4), p. 1117-1120-
dc.identifier.issn0300-9009-
dc.identifier.urihttp://hdl.handle.net/1942/37436-
dc.description.sponsorshipThis research received no specifc grant from any funding agency in the public, commercial, or not-for-proft sectors.-
dc.language.isoen-
dc.publisherSPRINGER HEIDELBERG-
dc.rightsThe Author(s) under exclusive licence to Belgian Neurological Society 2022-
dc.subject.otherMultiple sclerosis-
dc.subject.otherAlemtuzumab-
dc.subject.otherGraves’ disease-
dc.subject.otherOcrelizumab-
dc.subject.otherAutoimmunity-
dc.subject.otherTherapeutics-
dc.titlePost‑alemtuzumab Graves’ disease remitting after switch to ocrelizumab-
dc.typeJournal Contribution-
dc.identifier.epage1120-
dc.identifier.issue4-
dc.identifier.spage1117-
dc.identifier.volume122-
local.format.pages4-
local.bibliographicCitation.jcatA1-
dc.description.notesPopescu, V (corresponding author), Univ MS Centrum Pelt Hasselt, Noorderhart Hosp, Pelt, Belgium.; Popescu, V (corresponding author), Hasselt Univ, Hasselt, Belgium.-
dc.description.notesveronica.popescu@noorderhart.be-
local.publisher.placeTIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY-
local.type.refereedRefereed-
local.type.specifiedLetter-
dc.identifier.doi10.1007/s13760-022-01962-9-
dc.identifier.pmid35589913-
dc.identifier.isi000798323700002-
dc.identifier.eissn2240-2993-
local.provider.typeCrossRef-
local.description.affiliation[Popescu, Veronica] Univ MS Centrum Pelt Hasselt, Noorderhart Hosp, Pelt, Belgium.-
local.description.affiliation[Popescu, Veronica] Hasselt Univ, Hasselt, Belgium.-
local.description.affiliation[Beirinckx, Annemie] Gen Hosp Sint Lucas Bruges, Dept Endocrinol, Brugge, Belgium.-
local.description.affiliation[Decallonne, Brigitte] Univ Hosp Leuven, Dept Endocrinol, Leuven, Belgium.-
local.description.affiliation[Decallonne, Brigitte] Katholieke Univ Leuven, Clin & Expt Endocrinol, Leuven, Belgium.-
local.uhasselt.internationalno-
item.fulltextWith Fulltext-
item.contributorPOPESCU, Veronica-
item.contributorBeirinckx, Annemie-
item.contributorDecallonne, Brigitte-
item.fullcitationPOPESCU, Veronica; Beirinckx, Annemie & Decallonne, Brigitte (2022) Post‑alemtuzumab Graves’ disease remitting after switch to ocrelizumab. In: Acta neurologica belgica, 122 (4), p. 1117-1120.-
item.accessRightsRestricted Access-
item.validationecoom 2024-
crisitem.journal.issn0300-9009-
crisitem.journal.eissn2240-2993-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Post-alemtuzumab Graves’ disease remitting after switch to ocrelizumab.pdf
  Restricted Access		Published version564.2 kBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.